Latest Articles

Publication Date
All News Scientific
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Elevated CENPA Promotes Endometrial Cancer Progression - Docwire News

Elevated CENPA Promotes Endometrial Cancer Progression Docwire News

Published: May 12, 2026, 11:41 p.m.
Read Full Article
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive

Managing Progression After Immunotherapy in Endometrial Cancer OncLive

Published: May 5, 2026, 12:07 p.m.
Read Full Article
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Published: April 11, 2026, 11 a.m.
Read Full Article
Polkey reductions, progression models and disability analysis under scrutiny - VWV

Polkey reductions, progression models and disability analysis under scrutiny VWV

Published: Jan. 28, 2026, 3:56 p.m.
Read Full Article
Study Identifies E2F8 as Key Regulator of DTL and MAPK Pathway in Endometrial Cancer Progression - geneonline.com

Study Identifies E2F8 as Key Regulator of DTL and MAPK Pathway in Endometrial Cancer Progression geneonline.com

Published: Dec. 30, 2025, 4:33 a.m.
Read Full Article
Research Links Immune and Angiogenic Interactions to Endometriosis Progression - geneonline.com

Research Links Immune and Angiogenic Interactions to Endometriosis Progression geneonline.com

Published: Dec. 29, 2025, 9:38 p.m.
Read Full Article
Outlook for endometriosis: Progression, treatment success, and more - MedicalNewsToday

Outlook for endometriosis: Progression, treatment success, and more MedicalNewsToday

Published: Dec. 9, 2025, 2:13 p.m.
Read Full Article
T cells leads to functional abnormalities that promote endometriosis progression - BMC Medicine

T cells leads to functional abnormalities that promote endometriosis progression BMC Medicine

Published: Oct. 27, 2025, 1 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!